MYUNGMOON Pharm co.,Ltd (KRX:017180)
1,587.00
+1.00 (0.06%)
At close: Oct 31, 2025
MYUNGMOON Pharm co.,Ltd Revenue
MYUNGMOON Pharm co.,Ltd had revenue of 48.76B KRW in the quarter ending June 30, 2025, with 5.81% growth. This brings the company's revenue in the last twelve months to 190.76B, up 8.16% year-over-year. In the year 2024, MYUNGMOON Pharm co.,Ltd had annual revenue of 186.44B with 9.95% growth.
Revenue (ttm)
190.76B
Revenue Growth
+8.16%
P/S Ratio
0.28
Revenue / Employee
655.54M
Employees
291
Market Cap
52.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 186.44B | 16.88B | 9.95% |
| Dec 31, 2023 | 169.57B | 17.43B | 11.46% |
| Dec 31, 2022 | 152.13B | 14.38B | 10.43% |
| Dec 31, 2021 | 137.76B | 9.91B | 7.75% |
| Dec 31, 2020 | 127.85B | -21.49B | -14.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |